Pliant Therapeutics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced participation in the following investor conferences:

• Citi 16th Annual BioPharma Virtual Conference – Pliant’s senior management team will participate in one-on-one meetings with members of the investment community September 8 - 9, 2021
• Cantor 2021 Virtual Global Healthcare Conference – Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, will present on Wednesday, September 29, 2021, at 2:40 p.m. ET / 11:40 a.m. PT and, along with members of Pliant’s senior management team, will participate in one-on-one meetings with members of the investment community

The webcast replay of the Cantor conference presentation will be archived for 90 days following the conclusion of the event.

About Pliant Therapeutics, Inc.

Pliant is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 in the lead indications of IPF and PSC. Pliant has also developed PLN-1474, a small-molecule selective inhibitor of αvß1 for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis, which Pliant has transferred to Novartis pursuant to its development partnership. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant, visit www.pliantrx.com and follow us on Twitter, LinkedIn, Facebook, and YouTube.

Investor and Media Contact:

Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
[email protected]

You May Also Be Interested In

• Ted Trabue Appointed as Interim Chairman of the Public Service Commission of the District of Columbia
• AM Best Affirms Credit Ratings of Lloyd’s Syndicates 623, 2623, 3623 and 3622
• Bay Area Lyme Ventures Invests in LymeLess Health to Accelerate AI-Powered Innovation for Lyme & Tick-Borne Disease Patients